Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dalteparin
Drug ID BADD_D02459
Description Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Indications and Usage Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications. Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes). It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.
Marketing Status Not Available
ATC Code B01AB04
DrugBank ID DB06779
KEGG ID D03353
MeSH ID D017985
PubChem ID 772
TTD Drug ID D01ZJK
NDC Product Code Not Available
Synonyms Dalteparin | Tedelparin | FR-860 | FR 860 | FR860 | Kabi-2165 | Kabi 2165 | Kabi2165 | Dalteparin Sodium | Sodium, Dalteparin | Fragmin | Fragmine
Chemical Information
Molecular Formula C26H42N2O37S5
CAS Registry Number 9005-49-6
SMILES CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C( C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vaginal haemorrhage24.07.03.005; 21.08.01.0010.012704%
Visual impairment06.02.06.0080.012704%Not Available
Weight increased13.15.01.0060.012704%
Peripheral swelling08.01.03.053; 02.05.04.0150.025409%Not Available
Contusion24.07.06.001; 15.03.01.008; 23.03.11.002; 12.01.06.0010.025409%
Deep vein thrombosis24.01.02.0030.023199%Not Available
Malignant neoplasm progression16.16.01.0050.003314%Not Available
Haemorrhagic anaemia24.07.01.038; 01.03.02.0130.003314%Not Available
Transaminases increased13.03.01.0150.025409%Not Available
Haemorrhage24.07.01.0020.014914%Not Available
Intra-abdominal haematoma24.07.02.034; 07.12.02.0050.012704%Not Available
Bicytopenia01.03.03.0100.012704%Not Available
Blood alkaline phosphatase increased13.04.02.0040.012704%
Neoplasm progression16.16.02.0050.003314%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Renal impairment20.01.03.0100.031761%Not Available
Congenital foot malformation03.11.07.002; 15.11.07.0020.012704%Not Available
Heparin-induced thrombocytopenia24.01.01.020; 10.02.01.007; 01.08.01.0040.031761%Not Available
Blood count abnormal13.01.07.0010.012704%Not Available
Cytopenia01.03.03.0120.012704%Not Available
Renal cell carcinoma16.08.02.002; 20.01.04.0030.003314%Not Available
Cholestatic liver injury09.01.07.0160.003314%Not Available
Acute kidney injury20.01.03.0160.025409%
Gestational hypertension18.02.03.004; 24.08.07.0040.012704%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.019057%Not Available
Hepatic cancer16.07.02.004; 09.04.02.0080.003314%Not Available
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.0070.012704%Not Available
Maternal drugs affecting foetus18.03.03.009; 12.03.03.0060.019057%Not Available
Renal haematoma24.07.07.004; 20.01.02.018; 12.01.05.0060.003314%Not Available
Abdominal wall haematoma24.07.02.039; 07.16.05.0050.012704%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages